InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Advanced Radiotherapy is a game-changer for India’s cancer care burden
MUMBAI, India, Nov. 27, 2025 /PRNewswire/ -- In a country with over…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
November 26, 2025 19:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov.…
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025 16:06 ET | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md.,…
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as…
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025 21:56 ET | Source: Vor Biopharma BOSTON, Nov. 10,…
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting 2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in…